Get the Stockscreener App
0.415
5.01%
0.0198
After Hours:
.39
-0.025
-6.02%
Azitra Inc stock is traded at $0.415, with a volume of 238.36K.
It is up +5.01% in the last 24 hours and down -11.70% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.3952
Open:
$0.406
24h Volume:
238.36K
Relative Volume:
1.31
Market Cap:
$3.16M
Revenue:
$1.27M
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.1345
EPS:
-3.0856
Net Cash Flow:
$-10.46M
1W Performance:
-6.21%
1M Performance:
-11.70%
6M Performance:
+191.43%
1Y Performance:
-68.08%
1-Day Range:
$0.40
$0.4224
1-Week Range:
$0.3803
$0.4662
52-Week Range:
$0.0922
$12.00
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.415 | 3.16M | 1.27M | -11.28M | -10.46M | -22.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Azitra Inc Stock (AZTR) Latest News
Azitra, Inc. to Present at Biotech Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference - StreetInsider.com
Azitra to Present Growth Strategy at Biotech Showcase 2025: Clinical Pipeline & Development Plans in Focus - StockTitan
Azitra stock plunges to 52-week low, hits $0.42 - Investing.com India
Azitra, Inc. Announces Q3 2024 Financial Results and Provides Bu - GuruFocus.com
AZTR: Planning 2nd Site for ATR-12 Trial - MSN
Azitra stock plunges to 52-week low at $0.46 amid steep decline - Investing.com Australia
500: Something went wrong - Investing.com Canada
Azitra (NYSEAMERICAN:AZTR) Shares Down 3.9% – Here’s Why - Defense World
Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates - PR Newswire
Azitra to Present at BIO-Europe 2024 - BioSpace
Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit - Marketscreener.com
Azitra Joins 2024 Maxim Healthcare Virtual Summit - FinancialNews.co.uk
Netherton Syndrome Treatment Industry is Expected to Reach $8 Billion by 2034 -Lifemax Laboratories, Azitra, Inc, Sixera – IndiaPolitics.com - IndiaPolitics.com
Azitra stock plunges to 52-week low, hits $0.49 By Investing.com - Investing.com South Africa
Azitra stock plunges to 52-week low, hits $0.49 - Investing.com
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Azitra to present EGFR inhibitor toxicity treatment data By Investing.com - Investing.com Australia
Azitra to present EGFR inhibitor toxicity treatment data - Investing.com India
AZTRAzitra Inc Latest Stock News & Market Updates - StockTitan
Mexico's inflation undershoots forecasts ahead of rate decision - Investing.com
Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress - Business Wire
AZTR’s Market Fluctuations: Is Now the Right Time to Invest? - The InvestChronicle
FDA fast tracks Azitra's new dermatology treatment - Investing.com
Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors - StockTitan
Taking a Closer Look At Azitra Inc (AZTR) Following Its Recent Trade - Knox Daily
Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
Azitra (NYSEAMERICAN:AZTR) Stock Price Down 7.8% - Defense World
Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update - Defense World
Azitra Inc’s latest rating changes from various analysts - Knox Daily
A significant driver of top-line growth: Azitra Inc (AZTR) - SETE News
Financial Metrics Exploration: Understanding Azitra Inc (AZTR) Through Ratios - The Dwinnex
Do investors need to be concerned about Azitra Inc (AZTR)? - US Post News
Azitra doses first subject in Phase Ib Netherton syndrome treatment trial - Yahoo Finance
Azitra begins phase 1b trial for Netherton syndrome treatment - Investing.com
Views of Wall Street’s Leading Experts on Azitra Inc - SETE News
Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Trading Day Triumph: Azitra Inc (AZTR) Ends at 0.71, a -5.08 Surge/Plunge - The Dwinnex
Azitra Inc [AZTR] stock for 10,034 USD was bought by Staskey Norm - Knox Daily
FDA clears Azitra's Phase 1/2 trial for skin rash treatment - Investing.com
Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors - Marketscreener.com
A Look at Azitra Inc (AZTR) Shares in the Recent Past Indicates Growth - SETE News
Investing in Azitra Inc (AZTR) Is Getting More Attractive - Knox Daily
Azitra Inc Inc. (AZTR) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Cap:
|
Volume (24h):